FDA holds trials of Cellectis’ cell therapy after patient death
US regulators have placed on hold studies of French drugmaker Cellectis’ CAR-T therapy following a patient fatality.
Read More
Tag: Cellectis
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
- Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination
- HUTCHMED begins phase 3 stage of pancreatic cancer trial
